1. Introduction

An aberrant composition of the intestinal microbiota, or dysbiosis, is associated with a variety of intestinal and other disorders, such as infections and allergies, in humans (Alonso and Guarner, 2013). In the beginning of the 1900s, it was suggested for the first time to administrate ‘healthy’ bacteria to restore the microbial composition and thereby inducing a therapeutic effect (Metchnikoff, 1907). One approach to modulate the intestinal flora is the use of probiotics or prebiotics. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (FAO, 2001; Sanders, 2008). Prebiotics are non-viable food components that modulate the microbiota and thereby confer a health benefit on the host (Pineiro et al., 2008). When probiotics are administered in combination with prebiotics, it is referred to as a synbiotic (De Vrese and Schrezenmeir, 2008). There is still some controversy regarding the efficacy of pro- and synbiotics, as studies report inconsistent results. This might be attributable to different study populations (and power of the study) and conditions, probiotic strains, dosage and study duration (Sanders et al., 2013).

However, an ever expanding number of suitably powered, randomised controlled trials (RCT) with probiotic supplementation demonstrate encouraging results for particular conditions in infants. For instance, a double-blind RCT by Saavedra et al. (1994) demonstrated that administration of Streptococcus thermophilus and
Bifidobacterium bifidum in infants aging from 5 to 24 months reduced the incidence of acute diarrhoea and rotavirus shedding. Additionally, meta-analyses indicate that probiotic supplementation results in a reduction in diarrhoeal duration as well as a reduced incidence of Clostridium difficile induced diarrhoea (Goldenberg et al., 2013; Sanders et al., 2013). Probiotic interventions have also clearly demonstrated to significantly reduce the incidence of necrotising enterocolitis (NEC) in very-low-birth-weight (<1,500 g) preterm infants (Ganguli and Walker, 2011; Lin et al., 2013). Besides the beneficial effects of probiotics on gastrointestinal disorders, clinical data also indicate a potential in other disorders, such as the prevention of atopic dermatitis by Lactobacillus rhamnosus GG supplementation (Kalliomäki et al., 2001).

The intestinal microbiota supports the human body in various physiologic and metabolic functions, such as energy storage, fermentation, synthesising amino acids and vitamins (Vyas and Ragnanathan, 2012). Equally important is the major role of the intestinal microbiota in the development, maturation and maintenance of a ‘normal’ immune system (Kamada et al., 2013). Studies using germ-free mice demonstrate a poorly developed immune system and an altered intestinal morphology (Ping and Lanjuan, 2012). Gut bacteria are able to produce short-chain fatty acids, such as acetate, propionate, and butyrate, which acidify the intestinal lumen, thereby inhibiting pathogenic growth (Alonso and Guarner, 2013). In humans, the gut microbiota colonises the mucosal surface, thereby competing with potential pathogens for nutrition and binding sites (Kamada et al., 2013). Additionally, some commensal bacteria are able to produce antimicrobial and antifungal peptides, preventing pathogens from getting a foothold in the intestines (Hardy et al., 2013). Intestinal colonisation is also associated with a higher secretory immunoglobulin A concentration, which prevents microbes from penetrating the epithelium. Finally, the gut microbiota stimulates innate and adaptive immune response. Dendritic cells and Toll-like receptors are in close contact with the intestinal microbiota, probing in the lumen, and thereby shape the natural killer (NK)-cell, T-cell and B-cell response (Hardy et al., 2013).

The foetal intestine is sterile in the womb and microbial colonisation is initiated due to extensive contact in the birth canal during labour. The intestinal microbiota further matures by close contact with the environment and breast milk (Clemente et al., 2012). Neonates that fail to acquire the normal intestinal ecosystem are at risk of developing diseases, also later in life. Studies demonstrated that preterms, predominantly colonised by bacteria in the intensive care unit, tend to have a higher risk to develop an allergy and inflammatory bowel syndrome (Hickey et al, 2012). Formula-fed infants have a more heterogeneous microbial composition, which is associated with a higher incidence of infections and more Clostridia species in the intestine compared to breast-milk fed infants (Hascoët et al., 2011).

There are several concerns regarding the potential risk associated with probiotic use, especially in an immature or compromised gut. The bacteria may translocate through the gastrointestinal barrier, thereby causing invasive infections leading to bacteraemia or sepsis. Another concern is the possibility that the metabolic activity of the microbial products might be toxic to the host. Additionally, probiotics could even have an adverse immunologic effect (Hibbard and Davidson, 2008). Although probiotics have a good safety record in humans and are designated as GRAS (generally recognised as safe) by the FAO/WHO (Von Wright, 2005), when administered to preterm infants and neonates, profound analyses and safety aspects should be taken into account before considering a probiotic therapy. There is a consensus that immune-compromised and immune-deficient individuals are more susceptible to opportunistic bacteria due to defective microbial clearance.

At birth, infants do not have a fully developed immune system yet and, hence, could be at risk of fungemia and bacteraemia after probiotic administration (Boyle et al., 2006; Maròdi, 2006). Indeed, bacteraemia was reported in 3 infants with short-bowel syndrome after ingestion of L. rhamnosus GG (De Groote et al., 2005; Kunz et al., 2004). Due to insufficient understanding of the probiotic properties and the interaction in the gut, safety predictions remain inaccurate. Currently, it is difficult to conclude that probiotics are ‘safe’ in infants, as each individual strain has to be evaluated for safety at high dosage and chronic use.

In the aftermath of safety issues in pancreatitis, we suggested that results with probiotics could never be generalised (Maassen and Claassen, 2008) and an extensive (1994-2009) exploratory safety analysis of probiotics indicated there is no increased health risk (Claassen et al., 2010; Hempel et al., 2011). However, at that time the authors indicated that, due to poorly documented interventions and a lack of adverse event (AE) reporting, probiotic safety remains uncertain. This report aims to review the safety data of probiotic and symbiotic interventions focusing on the infant population ageing 0 to 24 months old. Specifically, it will provide an update (2008-2013) with the most recent intervention studies on the previous safety analysis by Hempel et al. (2011). This analysis will provide a clear overview of any safety concerns for high-dosage and chronic probiotic use in at-risk infant populations, by taking health conditions, probiotic intake and study duration into account.

2. Methodology

In order to analyse the safety of probiotics and symbiotics in infants, a comprehensive literature study was conducted. The online database PubMed (National Library of Medicine,
includes MEDLINE) was used as a source for the clinical studies. Eligible articles were retrieved using the search terms ‘probiotics’, ‘synbiotics’, ‘infants’ and ‘clinical trials’. This search strategy was complemented with filters to solely include human studies published within the last five years (2008-2013). Thereby, all animal and in vitro studies were excluded. A full literature search was performed to ensure that all the relevant studies were included. All studies were subsequently reviewed for clinical phase and status using the clinical trials registry databases ‘clinicaltrials.gov’ and ‘isrctn.org’. The articles were considered eligible if the researchers conducted an interventional study using a probiotic, a mixture of probiotics or synbiotics in infants ageing between 0 and 24 months. All original and follow-up studies were included, without probiotic species or study design restrictions. Both mechanistic studies as well as studies attempting to cure, treat, alleviate or prevent an illness were incorporated into this analysis. A total number of 139 studies describing a probiotic or synbiotic intervention in participants ageing from birth to 18 years were analysed for applicability based on the abstract of the publication. Subsequently, a full text analysis was conducted on 128 studies, as 11 studies could not be accessed or were not published in English. Forty-nine articles were excluded from the safety analysis because not all participants in the intervention arms were between 0 and 24 months of age. An additional six articles were excluded as no probiotic intervention was conducted during the study. Hence, the safety analysis was based on 65 studies, of which 57 and 8 were original and follow-up studies, respectively (Figure 1). The remaining eight papers concerned secondary analyses on previous studies and were therefore excluded from analysis.

The safety profile of the administered probiotics and synbiotics were assessed by means of the reported AEs, and analysed according to their nature and quantity. AEs are defined as the occurrence of complications or illnesses, or worsening of the condition throughout the study. AEs were categorised according to the Common Terminology Criteria for Adverse Events (CTCAE version 4.0, NIH, 2009) classification system (Table 1). The CTCAE divides the AEs into 26 categories and grades according to the severity. This study did not grade the severity of the AEs as these data were missing or difficult to interpret. An extra category ‘unspecified’ was added, as not all reported AEs could be properly categorised. AEs were not further subdivided into related or serious AEs, because this also depends on the judgement of the investigator and unrelated AEs might be related in a large meta-analysis. In some studies both the mother and infant received probiotic supplements. In these cases, only the AEs reported in the infants were taken into account. Other relevant data, such as probiotic strains, dosage, intervention duration and efficacy, were taken

![Figure 1. Literature search flow of the safety analysis.](http://www.wageningenacademic.com/doi/pdf/10.3920/BM2013.0046)
into account for additional analyses. It should be noted that this review uses the terms probiotics and synbiotics interchangeably, as the synbiotics contain probiotic strains.

3. Results

A total of 10,056 infants, between 0 and 24 months of age, were enrolled in the 57 eligible clinical intervention studies (analysed studies, Table 2). 5,643 infants were assigned to the treatment arm and 4,413 infants to the placebo arm, with a drop-out rate of 10.3 and 10.6% respectively. The data of the entire allocated population were used in the safety analysis, as these include drop-outs due to AEs, which are not included in the per-protocol population. Most studies were published between 2008 and 2012, whereas only one study was published in 2013. The participants were recruited according to their respective health status or illness, and could be subdivided into the following groups:

(1) no disorder, including the subgroups healthy, formula-fed, caesarean delivered, and at risk of allergy (one or more first degree relatives with an allergic disease) infants; (2) preterm infants, ranging from healthy to very low birth weight (<1,500 g); (3) infants suffering from intestinal disorders, which could be subdivided into the subgroups diarrhoea, infantile colic, chronic constipation and regurgitation; and (4) inflammatory disorders, encompassed atopic dermatitis, eczema and cow’s milk allergy.

As illustrated in Figure 2, the majority of infants received *L. rhamnosus* GG. In general, *L. rhamnosus* GG, *Lactobacillus reuteri* DSM 17938, *L. rhamnosus* LPR and *Bifidobacterium longum* BL999 were each administered to at least 450 participants. The strains *Bifidobacterium lactis* BB-12, *B. bifidum* CUL20, *B. bifidum* NCDO 1453, *B. lactis* CUL34, *Lactobacillus acidophilus* NCDO 1748, *Lactobacillus paracasei* CUL08 and *Lactobacillus salivarius* CUL61 were supplemented to between 200 and 450 participants each. Between 100 and 200 participants received the

### Table 1. The common terminology clinical adverse events (CTCAE) version 4.0. The CTCAE is a descriptive terminology, which can be utilised for adverse event (AE) reporting according to 26 categories. The 27th category ‘unspecified’ was added as not all reported AEs could be categorised.

<table>
<thead>
<tr>
<th>Category</th>
<th>Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>I</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>II</td>
</tr>
<tr>
<td>Congenital, familial and genetic disorders</td>
<td>III</td>
</tr>
<tr>
<td>Ear and labyrinth disorders</td>
<td>IV</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>V</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>VI</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>VII</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>VIII</td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
<td>IX</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>X</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>XI</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>XII</td>
</tr>
<tr>
<td>Investigations</td>
<td>XIII</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>XIV</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>XV</td>
</tr>
<tr>
<td>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</td>
<td>XVI</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>XVII</td>
</tr>
<tr>
<td>Pregnancy, puerperium and perinatal conditions</td>
<td>XVIII</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>XIX</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>XX</td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
<td>XXI</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>XXII</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>XXIII</td>
</tr>
<tr>
<td>Social circumstances</td>
<td>XXIV</td>
</tr>
<tr>
<td>Surgical and medical procedures</td>
<td>XXV</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>XXVI</td>
</tr>
<tr>
<td>Unspecified</td>
<td>XXVII</td>
</tr>
</tbody>
</table>

### Table 2. List of clinical studies evaluated.

<table>
<thead>
<tr>
<th>Abrahamsson et al., 2009, 2011</th>
<th>Mohan et al., 2008.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Hosni et al., 2012</td>
<td>Morisset et al., 2011</td>
</tr>
<tr>
<td>Allen et al., 2010</td>
<td>Nermes et al., 2011</td>
</tr>
<tr>
<td>Baldassarre et al., 2010</td>
<td>Niers et al., 2009</td>
</tr>
<tr>
<td>Basu et al., 2009</td>
<td>Ou et al., 2012</td>
</tr>
<tr>
<td>Braga et al., 2011</td>
<td>Panigrahi et al., 2008</td>
</tr>
<tr>
<td>Chouraqui et al., 2008</td>
<td>Rautava et al., 2009</td>
</tr>
<tr>
<td>Chrzanowska-Liszewska et al., 2012</td>
<td>Ritchie et al., 2010</td>
</tr>
<tr>
<td>Coccorullo et al., 2010</td>
<td>Rojas et al., 2012</td>
</tr>
<tr>
<td>Dekker et al., 2009</td>
<td>Romeo et al., 2011</td>
</tr>
<tr>
<td>Dutta et al., 2011</td>
<td>Rose et al., 2010</td>
</tr>
<tr>
<td>Fernández-Carrocera et al., 2012</td>
<td>Rouge et al., 2009</td>
</tr>
<tr>
<td>Firmansyah et al., 2011</td>
<td>Rozé et al., 2012</td>
</tr>
<tr>
<td>Gibson et al., 2009</td>
<td>Salmi et al., 2010</td>
</tr>
<tr>
<td>Gil-Campos et al., 2012</td>
<td>Samanta et al., 2008</td>
</tr>
<tr>
<td>Gore et al., 2012</td>
<td>Sari et al., 2012</td>
</tr>
<tr>
<td>Grundy et al., 2010</td>
<td>Savino et al., 2010</td>
</tr>
<tr>
<td>Haschke-Becher et al., 2008</td>
<td>Scalabrin et al., 2009</td>
</tr>
<tr>
<td>Hascoët et al., 2011</td>
<td>Soh et al., 2009, 2010</td>
</tr>
<tr>
<td>Hol et al., 2008</td>
<td>Szajewska et al., 2013</td>
</tr>
<tr>
<td>Holscher et al., 2012</td>
<td>Taipale et al., 2011, 2012</td>
</tr>
<tr>
<td>Indrio et al., 2008, 2009, 2011</td>
<td>Teran et al., 2009</td>
</tr>
<tr>
<td>Kopp et al., 2008</td>
<td>Underwood et al., 2009</td>
</tr>
<tr>
<td>Kuitunen et al., 2009a,b</td>
<td>Van der Aa et al., 2010,</td>
</tr>
<tr>
<td>Larsen et al., 2011</td>
<td>Velaphi et al., 2008</td>
</tr>
<tr>
<td>Lin et al., 2008</td>
<td>Vlieger et al., 2009</td>
</tr>
<tr>
<td>Lodinová-Žádníková et al., 2010</td>
<td>West et al., 2009</td>
</tr>
<tr>
<td>Luoto et al., 2010</td>
<td>Wickens et al., 2012</td>
</tr>
<tr>
<td>Maldonado et al., 2010, 2012</td>
<td>Yamasaki et al., 2012</td>
</tr>
<tr>
<td>Manzoni et al., 2009, 2011</td>
<td>Youngster et al., 2011</td>
</tr>
<tr>
<td>Mihatsch et al., 2010</td>
<td></td>
</tr>
</tbody>
</table>
Probiotic and synbiotic safety in infants under two years of age

Beneficial Microbes 5(1) 49


The other probiotic strains were administered to less than 100 participants, making their safety data less reliable. Probiotic species lacking proper strain designation is due

Figure 2. The range of daily cfu intake and participants for each probiotic strain.
to incomplete intervention description in the original studies. Figure 2 demonstrates the evaluated daily dosage for each probiotic culture depicted as minimal, maximal and average dosage in \( \text{cfu} \). On average, the infants received a total of \( 2.79 \times 10^{10} \text{ cfu/day} \) (4.23 \( \times \) \( 10^{8} \) \( \text{ cfu} \) without the two outliers), ranging from a maximal dosage of \( 2 \times 10^{12} \text{ cfu} \) with \( L. \ rhamnosus \) \( \text{GG} \) to the lowest dosage of \( 7 \times 10^{6} \text{ cfu} \) with \( S. \ thermophilus \) (unspecified). The strains \( L. \ rhamnosus \) \( \text{GG} \), \( L. \ rhamnosus \) \( \text{LPR} \) (CGMCC 1.3724), \( B. \ longum \) BL999 (ATCC: BAA 999), \( B. \ lactis \) \( \text{Bb-12} \) (ATCC: 27,536), \( B. \ infantis \), \( L. \ casei \), \( L. \ acidophilus \), \( B. \ longum \), \( L. \ rhamnosus \), \( B. \ bifidum \), \( Saccharomyces \) \( \text{boulardii} \) and \( L. \ paracasei \) \( \text{ST11} \) were evaluated for multiple dosages, whereas the other strains were only assessed at a single dosage or the daily applied \( \text{cfu} \) dosage was missing. As literature did not indicate a clear daily \( \text{cfu} \) dosage, data are missing for the strains \( B. \ bifidum \) NCDO 1453, \( L. \ acidophilus \) NCDO 1748, \( L. \ casei \) CRL-431 (ATCC: 55,544), \( B. \ breve \) C50, \( S. \ thermophilus \) 065 and \( L. \ salivarius \) CECT5713.

As not all health conditions or disorders require the same treatment strategy, particular conditions require specific probiotic properties and strains. Nevertheless, most studies administered \( L. \ rhamnosus \), regardless of the infant’s health status, except for infants with an immunologic disorder; the majority of these infants received \( B. \ lactis \). In preterms and infants with gastrointestinal disorders, \( L. \ reuteri \) was the most frequent studied probiotic, whereas for healthy infants and infants with an immune disorder this was \( B. \ lactis \) and \( L. \ casei \), respectively. When analysing on a specific strain basis, \( L. \ rhamnosus \) \( \text{GG} \) is evaluated in the majority of studies. However, in healthy infants, this is not the most investigated probiotic strain, as the majority of participants received \( B. \ longum \) BL999 (n=580). Figure 3 depicts the number of participants for each probiotic strain and the total number of studies performed using this strain, analysed for (a) healthy and (b) preterms infants.

Analysis of the study durations is depicted in Figure 4A. The mean intervention duration for the 57 trials was 121 days. Three studies did not define a clear study duration, but rather a clinical outcome as endpoint; hence, these studies were not being included in this analysis. The majority of the participants were exposed to probiotics, during a period of 6 months or shorter (46 studies). Only one study evaluated the effect of long-term exposure, as the participants received probiotics for 2 years. Infants suffering from diarrhoea had the shortest exposure (mean 5 days), whereas the infants at risk of developing an allergy received the study product during a mean of 266 days. The mean study duration for healthy and formula-fed infants was also more than 4 months.

Studies were analysed for the non-specific overall safety statement, independently of the reported AEs. These safety statements ranged from ‘no AEs were reported during the intervention’ and ‘the study product was well tolerated’ to ‘increased complications’. As stated in Figure 4B, 28 and 26% of the studies did not encounter any AEs or the AEs were not related to the study product, respectively. There was no significant difference in AEs between the treatment arm and the placebo arm in 12% of the studies, and 11% of the studies stated that the investigational product was well tolerated. Notably, 21% of the studies did not discuss or report AEs or any safety aspects. One study (2%) reported increased complications due to probiotic administration (Gore et al., 2012).

The administered dosage per condition is depicted in Figure 5A. The highest daily dosage range is applied to infants suffering from diarrhoeal disease; \( 2 \times 10^{7} \) to \( 2 \times 10^{12} \text{ cfu} \). Infants suffering from other gastrointestinal disorders, such as regurgitation and constipation, received on average the lowest \( \text{cfu} \) per day. Surprisingly, all formula-fed infants received a total of \( 1 \times 10^{10} \text{ cfu} \) per day. The lowest daily dosage of \( 7 \times 10^{6} \) was administered to preterm (low-birth-weight) infants, however they were exposed to an average of \( 2 \times 10^{8} \text{ cfu} \) per day.

Data from the follow-up studies did not indicate any safety concerns. A 10-year follow-up study by Luoto et al. (2010) reported no AEs or any effect on growth pattern and development of obesity by \( L. \ rhamnosus \) \( \text{GG} \). Van der Aa et al. (2011) demonstrated that, after a follow-up period of one year, infants receiving \( B. \ breve \) M-16V had less asthma-like symptoms compared to the placebo group. In addition, Kukkonen et al. (2008) showed that a mix of probiotics is safe on the long-term and increased resistance to respiratory infections.

The number of participants allocated and analysed ‘per protocol’ for each infant health condition is shown in Figure 6A. The majority of infants subjected to an intervention were preterms, infants at risk of allergy and healthy infants, respectively. The most common reported AEs were ‘diarrhoea’, ‘respiratory infections’, ‘gastrointestinal infections’, ‘sepsis’ and ‘fever’. Please note that this in itself is not surprising, since these effects were also the main clinical outcomes to be influenced by probiotics. However, in view of AE reporting this should not induce a bias in properly conducted studies. A total of 5,147 AEs were reported in the treatment and placebo group together. AEs in the category of infections and infestations (category XI) occurred most frequently, followed by gastrointestinal symptoms (category VII), respiratory, thoracic and mediastinal disorders (category XXII), and general disorders and administration site conditions, such as fever (category VIII). Figure 6B shows the distribution of AEs for the various CTCAE categories for all probiotic intervention arms and non-probiotic control arms. The AEs that occurred in the other categories were relatively rare. When focussing more closely on reported AEs within the
Figure 3. Participants and number of studies per culture in (A) preterm and (B) healthy infants. The gray bar represents the number of participants, the asterisk is the number of studies.
specific infant conditions, infections and infestations (XI) are most prevalent in preterm infants. In category XI, 100 more AEs were reported in the treatment arm compared to the control group. The incidence of gastrointestinal symptoms was lower in the verum group (Figure 6C). In infants suffering from diarrhoea, more AEs are reported in the treatment group for all CTCAE categories, although the number of AEs is very low compared to the number of allocated participants (Figure 6D). When focussing on reported AEs in infants with dermatitis, eye disorders (VI), gastrointestinal symptoms (VII) and immune system disorders (X), AEs are more frequently observed in treatment group compared to the placebo group, whereas skin and subcutaneous tissue disorders (XXIII) were less frequently reported in the treatment group (Figure 6E). In formula-fed infants, all AEs occurred more frequently in the control group, with the highest prevalence of infections and infestations (XI) (Figure 6F). In the healthy infant population, infections and infestations were most commonly observed, whereas in infants at-risk of developing an allergy,
Probiotic and synbiotic safety in infants under two years of age

Figure 6. (A) Participants allocated and analysed per protocol of the verum and placebo group for each health condition. (B) The total adverse events (AEs) reported of all studies, comparing placebo and verum group and categorised according to the Common Terminology Clinical Adverse Events (CTCAE). (C) Reported AEs categorised according to CTCAE analysed for preterm infants, (D) infants with diarrhoea, (E) infants with dermatitis, and (F) formula-fed infants.
gastrointestinal symptoms (VII) occurred more frequently. In addition, the incidence of AEs that could be categorized as gastrointestinal symptoms (VII, 207 and 180), fever episodes (VIII, 189 and 186) and respiratory, thoracic and mediastinal disorders (XXII) were high (n=226 and 197 for the treatment and placebo, respectively) in healthy infants. In infants affected by gastrointestinal disorders other than diarrhoea, few AEs were reported and often of gastrointestinal of nature (data not shown).

4. Discussion and conclusions

Analysis of the 57 clinical trials with probiotics and synbiotics in combination with eight follow-up studies, published between 2008 and 2013, indicate that probiotic administration to infants between 0 and 24 months is safe with regard to the evaluated strains in infants with a particular health status or susceptibility. Most AEs and serious AEs were considered unrelated to the study product, and there were no major safety concerns. Almost all studies concluded that none of the AEs were related to the study product and the study products are generally well tolerated. Only a single study reported increased complications, such as green loose stools, increased vomiting, feed-refusal or colic, although, prevalence and significance of AEs was not described (Gore et al., 2012). This study analysed whether dietary supplementation of infants with eczema at age 3-6 months with probiotics had a treatment effect or altered allergic disease progression. These infants ingested L. paracasei CNCM I-2116 or B. lactis CNCM I-3446 in combination with an extensively hydrolysed (EH) infant formula. This EH-infant formula could well have induced the AEs, as other studies using L. paracasei CNCM I-2116 and B. lactis CNCM I-3446 do not report any significant AEs (Chouraqui et al., 2008; Gibson et al., 2009; Velaphi et al., 2008). Gore and colleagues did also not report any significant clinical effect between the study groups, whereas previous studies analysing the effect of other probiotics in infants with eczema demonstrate a positive clinical results and no AEs (Weston et al., 2005; Rosenfeldt et al., 2003).

The data of this review indicate that there is no significant difference in the number of AEs between the probiotic and the control group; both in the total population as well as in the specific health conditions. A total of 2,589 and 2,558 AEs were reported in the treatment and control group, respectively. This subtle difference of 31 more AEs in the treatment arm is not significant as 1,230 more participants were allocated to this arm and hence relatively more AEs occurred in the control group (incidence rate of an AE=0.458 in the treatment group vs. 0.579 in the placebo group, respectively). The largest difference in participant allocation between treatment and placebo group was observed in the preterm study population. This deviation could be attributed to the retrospective study of Manzoni et al. (2011), analysing the effect of L. rhamnosus GG supplementation in preterm infants. This study did not include a control group, which explains the higher observed frequency of AEs. In particular, Manzoni et al. (2011) documented 142 cases of late-onset sepsis, in the category infections and infestations (XI). This explains that more AEs are observed in the probiotic group in category (XI). If these cases were subtracted from the total reported AEs in category XI, 86 more infections and infestations occurred in the control group. This would be consistent with other reports in the literature indicating that probiotics reduce the incidence of infections (Maldonado et al., 2012; Manzoni et al., 2009; Taipale et al., 2011).

Despite that 984 infants with diarrhoea were allocated to the treatment or control arm, surprisingly very few (18) AEs were reported in these studies. A proportion of these infants received a very high daily dosage of 2×10^{12} cfu L. rhamnosus GG, with no significant difference in AEs (Basu et al., 2009). These data are encouraging and further underpin the evidence that L. rhamnosus GG is safe in infants, even at a very high dosage. The strain L. rhamnosus GG is well characterised and evaluated in a large population sample at varying dosages. Unfortunately, this is not the case for many other potential beneficial probiotic strains. For many infant health conditions, daily intake did not exceed 1×10^{10} cfu. Especially in healthy infants, the range of administrated dosage is relatively narrow, and these infants are the least susceptible for complications compared to other health conditions. Examining higher probiotic exposure in this healthy group could facilitate the establishment of the optimal dosage for infants.

In infants affected by dermatitis, the number of AEs in the category eye disorders (VI) and allergies (X) were substantially higher in the treatment group compared to placebo. This was mainly due to the study by Gore et al. (2012) that observed significantly more frequently itchy and red eyes at the age of 12 months in the probiotic group. However this significant difference was not persistent at later visits. Whether this is due to the EH-infant formula or the probiotic strains should still be determined.

Despite the large number of reported AEs in the clinical trials, only 21 studies observed a significant difference in AEs between the treatment and control arm. In most of these cases, probiotic treatment had a protective effect; in the control groups the frequencies of the occurred AEs were significantly higher. Despite these encouraging results, there were some safety concerns. Scalabrini et al. (2009) reported excessive crying in formula-fed infants and Kopp et al. (2008) observed a significant higher incidence of recurrent wheezing bronchitis in infants at risk of allergy after L. rhamnosus GG supplementation. Although a significant safety concern, this only occurred in a small sample (n=54) and was not observed in any other analysed clinical study with L. rhamnosus GG. In contrast to the other clinical
trials, probiotic administration of *B. longum* BL999 and *L. rhamnosus* LPR induced more episodes of diarrhoea in healthy infants compared to placebo (Firmansyah *et al.*, 2011). This increase in diarrhoea might be due to the fructose-oligosaccharide or other prebiotic additives in the study product, which were not present in the control product. The majority of analysed studies do not indicate any difference in respiratory tract infections between either intervention arms, or even demonstrate a slight protective effect against respiratory tract infections. Nevertheless, Allen *et al.* (2010) observed a higher frequency of lower respiratory tract infections when exposed to a probiotic mixture of *L. salivarius* CUL61, *L. paracasei* CUL08, *Bifidobacterium animalis* subsp. *lactis* CUL34 and *B. bifidum* CUL20.

No study reported a bacteraemia or fungemia associated with the ingested probiotics. This is in line with the literature. Since 1980s, there has been no increase in frequency of *Lactobacillus* associated bacteraemia cases in Finland, despite a substantial increase in probiotic use (Salminen *et al.*, 2002). Clinical infections, such as bacteraemia and myocarditis, are rarely (over a period of 10 years covering an population of 1.3 million persons where probiotics are standard in the diet; Salminen *et al.*, 2002) associated with the use of the probiotics *Lactobacillus* or *Bifidobacterium*. Also in a large study (in subjects with severe underlying disease!) evaluating 89 cases of *Lactobacillus* bacteraemia (unrelated to probiotic intake) treatment with antimicrobials was effective both *in vitro* and in reducing mortality (odds ratio = 0.22; Salminen *et al.*, 2004). In another very large survey, only 12 cases of bacteraemia were reported concurrent with the use of *L. rhamnosus* GG, 5 cases with *Bacillus subtilis* and 1 case with *L. acidophilus*. There were only 27 reports of fungemia when the yeast *S. boulardii* concurrently was administered, and the authors concluded probiotics are safe but results cannot be generalised for other or new/future strains (Boyle *et al.*, 2006).

Although the primary goal was not to identify the efficacy of probiotic interventional studies, most studies reported a significant beneficial clinical outcome effect. Increased stool frequency, softer stools and reduced diarrhoea were among the most common clinical effects. Despite the limited overall effects, in specific health conditions, such as preterms and infants suffering from diarrhoea, results are more promising; probiotics seem to prevent NEC (Bell's stage II and higher) and reduce the duration and hospitalisation in diarrhoea (Fernández-carrocera *et al.*, 2012; Grandy *et al.*, 2010; Lin *et al.*, 2008; Teran *et al.*, 2009). Nevertheless, 11 studies did not report any significant effect in the treatment arm compared to the control group, thereby maintaining the controversy of probiotic efficacy. Large meta-analyses should provide overall benefit/risk analyses and conclusions, and underpin policies for implementation of probiotic treatment.

Based on the study by Hempel *et al.* (2011) combined with the current data, we still cannot provide a decisive safety profile of probiotics and synbiotics. The documentation of the clinical studies is poor, as they lack details regarding AE, the specific identity of probiotic strains and administered dosage. Very few studies address specifically probiotic complications and are not designed to assess the safety profile. Additionally, safety should be evaluated on a strain-by-strain basis, depending on long-term and high dosage exposure.

A major pitfall of this safety analysis is the lack of consistent AE reporting. Many studies do not provide the incidence of AE, however, only state that ‘no significant difference in complications was observed between the study groups.’ Studies fail in particular to report the frequency of more common AEs, such as diarrhoea, vomiting, regurgitation, fever and flatulence, and focus more on irregular AEs. Incidences of serious AEs are often not well described and designated as unrelated to the study product, while large meta-analyses could give new insight in the causal relation of AE and the use of probiotics. The lack of this data inhibits a clear overview of the incidence of real complications and explains potential underrepresentation of certain CTCAE categories.

Another major flaw is the incorrect documentation of probiotic strains. Probiotics should be properly characterised according to the taxonomy, including specific strain and culture. Many studies fail to do this. Since beneficial effects on the host can only be attributed to a specific culture, selecting the correct probiotic strain is essential. Even if bacteria share the same genus and species, their properties can differ significantly and thus need to be tested individually (Van Baarlen *et al.*, 2011). Another shortcoming is that not all studies provide and mention a clear daily dosage (cfu) and duration of intervention. Studies that administer infant formula supplemented with probiotics do indicate the cfu/g; however, they fail to indicate the ingested cfu/day. A minimal concentration of probiotics is necessary to gain successful colonisation, which is often transient of nature (Petschow *et al.*, 2005). This missing data prevents the establishment of an optimal dose-response relationship. A higher probiotic dosage could induce a higher incidence of AEs. This review shows that the ranges of evaluated dosages are narrow for many infant conditions, and few studies administered probiotics at very high dosages. Research should focus on the efficacy of a single probiotic, a probiotic mixture or synbiotics. To obtain reliable data, studies should be well designed to test efficacy, preferably randomised, placebo controlled, double blinded studies. It is of importance that the probiotics or synbiotics have a well-defined target population. By
evaluating safety and efficacy on subgroups, including high-risk groups, the beneficial health effects can only be attributed to specific probiotic strains and for a certain health status. Investigators and industry should be aware that strain specific safety and efficacy data on particular patient populations should not be extrapolated to other probiotic strains or target populations.

5. Recommendations

Based on the probiotic format, target indication and mode of administration, a probiotic product can be characterised as a food, food supplement, biological or pharmaceutical product. These products are all subject to different regulations, which complicates safety guidelines and health claims. If probiotic products are used to prevent, treat, or alleviate a medical condition, the product should be considered as a biological product and evaluated according to the International Conference on Harmonisation of Technical Requirements – Good Clinical Practice and medical product procedures to produce consistent safety and efficacy data. This includes detailed descriptions of the studied product, and a comprehensive AE documentation.

Each new probiotic strain should be analysed for properties, including genomics, to understand the mode of action. Metabolic mechanisms, interaction with the host immunity and ability to exchange virulence factors with pathogens is essential for a comprehensive safety profile. Even if the probiotic strain is considered safe, it can still become opportunistic and cause bacteraemia. Probiotics should be considered safe if they at least fulfil the following specific criteria: (a) the probiotic strain should be properly isolated and classified according to the correct taxonomy; (b) manufactured according to good manufacturing practices to eliminate contamination with other microbes, probiotics or substances; (c) a clear overview of the safety (according to standardised and accepted CTCAE) and toxicity levels associated with the probiotic administration; and (d) a clear evaluation of the target population, including high risks groups such as infants and immune deficient patients.

Acknowledgements

We would like to thank Joop Orsouw for optimisation of the figures.

References


